ClinicalTrials.gg
CompletedNCT06660069Updated Mar 18, 2026Results posted

A Study to Evaluate the Efficacy of a Stannous Fluoride Toothpaste With a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation

An interventional study of Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste) and CPC Mouthwash (Parodontax Active Gum Health Mouthwash) in Dental Plaque and Gingivitis, sponsored by HALEON. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by HALEON · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
199
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Dental Plaque with a site in United States — 7 open to participants now, 8 under way, 1 of them phase 3. Dental Plaque · United States.

Enrollment
8th of 59
199 · median 80
Started
2024
with 4 others
No phase
33 of 65
6 open now
Registered
51st of 65
by date
Lead sponsor
4 of 65
HALEON

Among the 65 studies in Dental Plaque with a site in United States, this one is the 8th largest by enrollment of the 59 interventional ones that give a count, is one of 5 that started in 2024, is one of 33 with no phase, and was the 51st registered.

Dental Plaque

352 studies on the registry are indexed under Dental Plaque; 60 are open to participants now.

Browse Dental Plaque studies →

Open to participants now

7 of the 65 studies in Dental Plaque with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Dental Plaque studies recruiting now, 10 (29%) set no upper age limit and 20 (57%) stop at 75 or younger; 14 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Dental Plaque with a site in United States, or all of them as a file.
02

Study summary

The aim of this study is to assess the ability of a marketed Cetylpyridinium Chloride (CPC) mouthwash alongside a marketed Stannous Fluoride (SnF2) toothpaste in improving gingival health and reducing plaque accumulation, compared to the use of a regular fluoride toothpaste alone in participants with clinically measurable plaque-induced gingivitis.

Read the detailed description

This will be a single center, 12-week, randomized, controlled, examiner-blind, 3-treatment arm, parallel group, stratified (by sex [male/female]) study to evaluate the efficacy of using the SnF2 toothpaste/CPC mouthwash twice daily in reducing gingivitis and plaque accumulation in a population with clinically measurable levels of gingivitis. The clinical efficacy of the commercially available SnF2 toothpaste/CPC mouthwash will be compared with that of a commercially available, regular fluoride toothpaste with no known anti-gingivitis nor anti-plaque efficacy properties (negative control). This study will also explore whether a CPC mouthwash used with a SnF2 toothpaste could provide benefits in plaque accumulation reduction and gingival health improvement over the sole use of SnF2 toothpaste (reference product). Sufficient participants will be screened to randomize approximately 198 participants (approximately 66 per group) to ensure approximately 180 evaluable participants (approximately 60 per group) complete the study.

03

Conditions studied

  • Dental Plaque
  • Gingivitis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant provision of a signed and dated document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
  • Participant is of either sex and any gender who, at the time of screening, is at least 18 years old, inclusive.
  • A participant who is willing and able to comply with scheduled visits, treatment plan and other study procedures.
  • A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.
  • Participant oral health that meets all the following:

AT SCREENING (Visit 1):

  1. Participant with at least 20 natural, permanent teeth.
  2. Participant with at least 40 evaluable surfaces for MGI, BI, and TPI.
  3. A participant with plaque-induced gingivitis, in the opinion of the clinical examiner, as confirmed by a gross visual examination at the Screening Visit.

AT BASELINE (Visit 2; Prior to Dental Prophylaxis):

  1. A participant with 10% - 30% bleeding sites.
  2. A participant with mean interproximal whole mouth TPI score >=1.5.

Exclusion criteria

Exclusion Criteria:

  • A participant who is an employee of the site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or, a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
  • A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
  • A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  • A participant who has any other clinical serious or unstable conditions (example, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) which could have affected study outcomes and/or participant safety.
  • A participant who is a pregnant female (self-reported) or intending to become pregnant over the duration of the study.
  • A female participant who is breastfeeding.
  • A participant with known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • A participant unwilling or unable to comply with the Lifestyle Considerations described in this protocol.
  • A participant who is a current smoker or an ex-smoker (including vaping) who stopped within 6 months of Screening.
  • A participant who is using smokeless forms of tobacco (example, chewing tobacco, gutkha, pan containing tobacco, nicotine-based e-cigarettes).
  • A participant who is diagnosed xerostomia or is taking any medication that in the view of the investigator is causing xerostomia.
  • A participant who has a medical condition which could have directly influenced gingival bleeding (example, type 2 diabetes).
  • A participant who has a bleeding disorder that could have affected study outcomes and/or participant safety.
  • A participant who has a recent history (within the last year) of alcohol or other substance abuse.
  • A participant who has a severe oral condition (example, acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.
  • Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.
  • Medication exclusions: At screening (Visit 1):

    1. A participant using any antibiotic medication within 4 weeks prior to screening or at any time during the study.
    2. A participant currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.
    3. A participant currently taking a systemic medication (example, anti-inflammatory, anticoagulant, ) or traditional/ herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
    4. A participant who has used an antibacterial dentifrice or mouthwash (example, chlorhexidine) or any oral care product that in the view of the investigator could interfere with plaque formation or measures of gingivitis, within 4 weeks prior to screening.
  • Medication exclusions: At Baseline (Visit 2):

    1. A participant who has taken (in the previous 4 weeks), any antibiotics.
    2. A participant who has taken (in the previous 4 weeks) a systemic medication (example, anti-inflammatory, anti-coagulant, immunosuppressants) or traditional/ herbal remedy (example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
    3. A participant who has used an antibacterial dentifrice or mouthwash (example, chlorhexidine) or any oral care product that in the view of the investigator could interfere with plaque formation or measures of gingivitis, in the period between Screening and the Baseline visit.
  • Periodontal exclusions:

    1. A participant who has more than three tooth sites with probing pocket depth >= 4 mm.
    2. A participant who is receiving or has received treatment for periodontal disease (including surgery) within 12 months of Screening.
    3. A participant who has gingivitis, which in the opinion of the investigator, is not expected to respond to treatment with an over the counter (OTC) dentifrice.
  • Dental Exclusions:

    1. A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    2. A participant who has dentures (partial or full).
    3. A participant who has an orthodontic appliance (bands, appliances, or fixed/removable retainers).
    4. A participant who received orthodontic therapy within 3 months of Screening.
    5. A participant who has numerous restorations in a poor state of repair.
    6. A participant who has any dental condition (example, overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    7. A participant who has had dental prophylaxis within 12 weeks of Screening.
    8. A participant who has had teeth bleaching within 12 weeks of Screening.
    9. A participant who has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could have interfered with plaque assessments.
  • A participant who has previously been enrolled in this study.
  • A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
199 participants (actual)

Study arms

  • Experimental
    Toothpaste/Mouthwash (SnF2 Toothpaste followed by CPC Mouthwash)

    Participants will brush their teeth with full ribbon of test toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks. After each brushing, participants will swish 20 milliliters (mL) of the mouthwash containing CPC vigorously between teeth for 30 seconds twice daily (morning and evening) for 12 weeks.

    Drug: Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste) · Drug: CPC Mouthwash (Parodontax Active Gum Health Mouthwash)

  • Active comparator
    Negative Control Toothpaste (Sodium Fluoride Toothpaste)

    Participants will brush their teeth with full ribbon of negative control toothpaste containing sodium fluoride on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.

    Drug: Regular Fluoride Toothpaste (Crest Cavity Protection)

  • Active comparator
    Reference Toothpaste (SnF2 Toothpaste)

    Participants will brush their teeth with full ribbon of reference toothpaste containing SnF2 on head of toothbrush provided for at least one (timed) minute twice daily (morning and evening) for 12 weeks.

    Drug: Stannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)

Interventions

  • DrugStannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)

    Toothpaste containing 0.454 percent (%) weight by weight (w/w) SnF2.

  • DrugCPC Mouthwash (Parodontax Active Gum Health Mouthwash)

    Mouthwash containing 0.07% w/w CPC.

  • DrugRegular Fluoride Toothpaste (Crest Cavity Protection)

    Toothpaste containing 0.243% w/w sodium fluoride.

  • DrugStannous Fluoride Toothpaste (Parodontax Complete Protection Toothpaste)

    Toothpaste containing 0.454% w/w SnF2.

06

What researchers measure

Primary outcomes

  1. Overall Number of Bleeding Sites (NBS) at Week 12 (Toothpaste/Mouthwash Versus [vs.] Negative Control Toothpaste)

    Gingival bleeding was assessed according to the expanded bleeding index (EBI), by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.

    Time frame: Week 12

Secondary outcomes

  1. Interproximal NBS at Week 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.

    Time frame: Week 12

  2. Overall NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.

    Time frame: Week 6

  3. Interproximal NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.

    Time frame: Week 6

  4. Mean Overall Bleeding Index (Bl) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0 equal to (=) no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  5. Mean Interproximal BI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  6. Mean Overall Modified Gingival Index (MGI) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

    The MGI assessment was a non-invasive evaluation which focused on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  7. Mean Interproximal MGI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

    The MGI assessment was a non-invasive evaluation which focused on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  8. Mean Overall Turesky Plaque Index (TPI) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

    The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/ palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 millimeter\[mm\]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (\<)1/3 of the tooth surface, 4= Plaque covering greater than or equal to (\>=) 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  9. Mean Interproximal TPI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

    The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  10. Overall NBS at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.

    Time frame: Week 6 and Week 12

  11. Interproximal NBS at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.

    Time frame: Week 6 and Week 12

  12. Mean Overall BI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI will be calculated by taking the average over all tooth sites assessed for a participant. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  13. Mean Interproximal BI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

    Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  14. Mean Overall MGI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

    The MGI assessment was non-invasive evaluation which focuses on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  15. Mean Interproximal MGI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

    The MGI assessment was non-invasive evaluation which focuses on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  16. Mean Overall TPI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

    The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores was recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

  17. Mean Interproximal TPI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

    The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.

    Time frame: Week 6 and Week 12

07

Results

Posted Mar 18, 2026

Participant flow

This study was conducted at a single center in United States of America.

Participant flow — Overall Study
MilestoneToothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Reference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Started656566
Completed636159
Not completed247
Withdrew: Lost to follow-up120
Withdrew: Withdrawal by subject127

Outcome measures

PrimaryOverall Number of Bleeding Sites (NBS) at Week 12 (Toothpaste/Mouthwash Versus [vs.] Negative Control Toothpaste)

Gingival bleeding was assessed according to the expanded bleeding index (EBI), by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth were assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.

Time frame:
Week 12
Reported as:
Least squares mean · bleeding sites
Overall Number of Bleeding Sites (NBS) at Week 12 (Toothpaste/Mouthwash Versus [vs.] Negative Control Toothpaste)
bleeding sitesToothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Overall Number of Bleeding Sites (NBS) at Week 12 (Toothpaste/Mouthwash Versus [vs.] Negative Control Toothpaste)10.1 ± 1.0324.1 ± 1.05
Statistical analysis
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -14.0 · 95% CI -16.9 to -11.1
SecondaryInterproximal NBS at Week 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.

Time frame:
Week 12
Reported as:
Least squares mean · bleeding sites
Interproximal NBS at Week 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
bleeding sitesToothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Interproximal NBS at Week 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)4.5 ± 0.7215.0 ± 0.74
Statistical analysis
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -10.5 · 95% CI -12.6 to -8.4
SecondaryOverall NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.

Time frame:
Week 6
Reported as:
Least squares mean · bleeding sites
Overall NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
bleeding sitesToothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Overall NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)10.6 ± 1.0925.0 ± 1.09
Statistical analysis
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -14.4 · 95% CI -17.4 to -11.3
SecondaryInterproximal NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.

Time frame:
Week 6
Reported as:
Least squares mean · bleeding sites
Interproximal NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
bleeding sitesToothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Interproximal NBS at Week 6 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)5.1 ± 0.7615.4 ± 0.76
Statistical analysis
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -10.3 · 95% CI -12.5 to -8.2
SecondaryMean Overall Bleeding Index (Bl) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0 equal to (=) no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Overall Bleeding Index (Bl) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
score on a scaleToothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 60.08 ± 0.0090.20 ± 0.009
Week 120.08 ± 0.0090.19 ± 0.009
Statistical analysis
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.12 · 95% CI -0.14 to -0.09
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.11 · 95% CI -0.13 to -0.09
SecondaryMean Interproximal BI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Interproximal BI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
score on a scaleToothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 60.06 ± 0.0090.18 ± 0.009
Week 120.05 ± 0.0090.17 ± 0.009
Statistical analysis
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.12 · 95% CI -0.15 to -0.10
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.12 · 95% CI -0.14 to -0.09
SecondaryMean Overall Modified Gingival Index (MGI) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

The MGI assessment was a non-invasive evaluation which focused on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Overall Modified Gingival Index (MGI) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
score on a scaleToothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 60.93 ± 0.0321.43 ± 0.032
Week 120.78 ± 0.0271.31 ± 0.027
Statistical analysis
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.50 · 95% CI -0.59 to -0.41
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.53 · 95% CI -0.61 to -0.45
SecondaryMean Interproximal MGI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

The MGI assessment was a non-invasive evaluation which focused on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Interproximal MGI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
score on a scaleToothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 61.13 ± 0.0331.62 ± 0.033
Week 120.97 ± 0.0271.49 ± 0.028
Statistical analysis
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.49 · 95% CI -0.58 to -0.39
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.52 · 95% CI -0.60 to -0.45
SecondaryMean Overall Turesky Plaque Index (TPI) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/ palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 millimeter\[mm\]) at the cervical margin, 3= Band of plaque wider than 1 mm but covering less than (\<)1/3 of the tooth surface, 4= Plaque covering greater than or equal to (\>=) 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Overall Turesky Plaque Index (TPI) at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
score on a scaleToothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 62.59 ± 0.0452.95 ± 0.046
Week 122.38 ± 0.0522.83 ± 0.054
Statistical analysis
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren test · p = 0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.37 · 95% CI -0.49 to -0.24
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.45 · 95% CI -0.59 to -0.30
SecondaryMean Interproximal TPI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)

The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Interproximal TPI at Weeks 6 and 12 (Toothpaste/Mouthwash vs. Negative Control Toothpaste)
score on a scaleToothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 62.88 ± 0.0403.19 ± 0.041
Week 122.69 ± 0.0483.10 ± 0.049
Statistical analysis
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.31 · 95% CI -0.42 to -0.20
  • Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.41 · 95% CI -0.55 to -0.27
SecondaryOverall NBS at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · bleeding sites
Overall NBS at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
bleeding sitesReference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 614.1 ± 1.0925.0 ± 1.09
Week 1211.4 ± 1.0424.1 ± 1.05
Statistical analysis
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -10.8 · 95% CI -13.9 to -7.8
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -12.7 · 95% CI -15.6 to -9.8
SecondaryInterproximal NBS at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing. The NBS for each participant was calculated as the number of evaluable tooth sites (having two-thirds of the natural tooth surface gradable for the assessment) with bleeding observed immediately on probing or within 30 seconds of probing.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · bleeding sites
Interproximal NBS at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
bleeding sitesReference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 67.8 ± 0.7615.4 ± 0.76
Week 126.1 ± 0.7315.0 ± 0.74
Statistical analysis
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -7.6 · 95% CI -9.7 to -5.5
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -8.8 · 95% CI -10.9 to -6.8
SecondaryMean Overall BI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI will be calculated by taking the average over all tooth sites assessed for a participant. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Overall BI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
score on a scaleReference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 60.11 ± 0.0090.20 ± 0.009
Week 120.08 ± 0.0090.19 ± 0.009
Statistical analysis
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.09 · 95% CI -0.11 to -0.06
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.10 · 95% CI -0.13 to -0.08
SecondaryMean Interproximal BI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

Gingival bleeding was assessed according to the EBI, by inserting a periodontal probe into the gingival crevice and sweeping from distal to mesial around the tooth at an approximate angle of 60 degrees, while in contact with the sulcular epithelium. Each of six gingival areas (distobuccal, midbuccal, mesiobuccal, distolingual, midlingual, and mesiolingual) around each tooth was assessed. Presence/absence of gingival bleeding was assessed for 30 seconds after probing and scored on a 3-points scale ranging from 0 to 2, where 0=no bleeding after 30 seconds; 1=bleeding observed within 30 seconds of probing; 2=bleeding observed immediately on probing. Mean BI was calculated by taking the average over all tooth sites assessed for a participant. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Interproximal BI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
score on a scaleReference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 60.09 ± 0.0090.18 ± 0.009
Week 120.06 ± 0.0090.17 ± 0.009
Statistical analysis
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.09 · 95% CI -0.12 to -0.07
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren Test · p = <0.0001 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.10 · 95% CI -0.13 to -0.08
SecondaryMean Overall MGI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

The MGI assessment was non-invasive evaluation which focuses on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Overall MGI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
score on a scaleReference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 61.11 ± 0.0321.43 ± 0.032
Week 120.88 ± 0.0271.31 ± 0.027
Statistical analysis
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.31 · 95% CI -0.40 to -0.23
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.43 · 95% CI -0.51 to -0.36
SecondaryMean Interproximal MGI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

The MGI assessment was non-invasive evaluation which focuses on the visual symptoms of gingivitis (for example, redness, texture, edema). MGI was assessed on the buccal and lingual marginal gingiva and interdental papillae of all scorable teeth (second permanent molar to second permanent molar in each arch) and scored on a 5-point scale ranging from 0 to 4, where 0=Absence of inflammation; 1=Mild inflammation; slight change in colour, little change in colour; little change in texture of any portion of the marginal or papillary gingival unit; 2=Mild inflammation; criteria as 1 but involving the entire marginal or papillary gingival unit; 3=Moderate inflammation; glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit; 4=Severe inflammation; marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Interproximal MGI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
score on a scaleReference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 61.31 ± 0.0321.62 ± 0.033
Week 121.06 ± 0.0271.49 ± 0.028
Statistical analysis
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.31 · 95% CI -0.40 to -0.22
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Mixed Model for Repeated Measures · p = <0.0001 · Adjusted mean difference: -0.43 · 95% CI -0.51 to -0.36
SecondaryMean Overall TPI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores was recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Overall TPI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
score on a scaleReference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 62.88 ± 0.0452.95 ± 0.046
Week 122.74 ± 0.0532.83 ± 0.054
Statistical analysis
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren test · p = 0.8986 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.07 · 95% CI -0.20 to 0.06
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren test · p = 0.5524 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.09 · 95% CI -0.24 to 0.06
SecondaryMean Interproximal TPI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)

The TPI was used to assess plaque on the facial and lingual surfaces of each scorable tooth (second molar to second molar). Three scores were recorded buccally/labially (distal, body, mesial sites) and three scores lingually/palatally (distal, body, mesial sites) and mean was calculated. The plaque was first be disclosed using a plaque disclosing dye solution and the disclosed plaque was scored on a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin, continuous band of plaque (up to 1 mm) at the cervical margin, 3= Band of plaque wider than 1 mm but covering \<1/3 of the tooth surface, 4= Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5= Plaque covering \>= 2/3 of the tooth surface. Lower score indicated improvement in the symptoms.

Time frame:
Week 6 and Week 12
Reported as:
Least squares mean · score on a scale
Mean Interproximal TPI at Weeks 6 and 12 (Reference Toothpaste vs. Negative Control Toothpaste)
score on a scaleReference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Week 63.15 ± 0.0403.19 ± 0.041
Week 123.02 ± 0.0493.10 ± 0.049
Statistical analysis
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren test · p = 0.8658 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.04 · 95% CI -0.16 to 0.07
  • Reference Toothpaste (SnF2 Toothpaste) vs Negative Control Toothpaste (Sodium Fluoride Toothpaste) · Van Elteren test · p = 0.2468 (Method used for estimates and P-values was MMRM. Where MMRM assumptions are violated, a supportive non-parametric P-value is used (Van Elteren Test) and presented here.) · Adjusted mean difference: -0.09 · 95% CI -0.22 to 0.05

Adverse events

Collected over Immediately after completion (signature) of the Informed consent form (ICF) and until 5 days following last administration of the study product (or last procedure) (Approximately up to 103 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)0/65 (0%)0/65 (0%)19/65 (29.2%)
Reference Toothpaste (SnF2 Toothpaste)0/65 (0%)0/65 (0%)6/65 (9.2%)
Negative Control Toothpaste (Sodium Fluoride Toothpaste)0/66 (0%)0/66 (0%)2/66 (3%)
Most frequent other events
Most frequent other events
EventToothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Reference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)
Tooth DiscolourationGastrointestinal disorders14/651/650/66
Aphthous UlcerGastrointestinal disorders2/652/650/66
Oral Mucosal ExfoliationGastrointestinal disorders2/651/651/66
Tongue CoatedGastrointestinal disorders2/651/650/66
Coronavirus Test PositiveInvestigations0/651/650/66
Taste DisorderNervous system disorders1/650/650/66
SinusitisInfections and infestations0/650/651/66

Baseline characteristics

Safety population- comprised all randomized participants who received at least one dose of investigational product.

Age, Continuous
Age, Continuous(years)Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Reference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)Total
Mean51.8 ± 14.3647.6 ± 14.3250.7 ± 13.3850.1 ± 14.06
Sex: Female, Male
Sex: Female, Male(Participants)Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Reference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)Total
Female555554164
Male10101232
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Reference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)Total
Hispanic or Latino44412
Not Hispanic or Latino616162184
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Toothpaste/Mouthwash (SnF2 Toothpaste Followed by CPC Mouthwash)Reference Toothpaste (SnF2 Toothpaste)Negative Control Toothpaste (Sodium Fluoride Toothpaste)Total
African American/African Heritage46616
American Indian or Alaskan Native0011
Asian - South East Asian Heritage1001
White - Arabic/North African Heritage42410
White - White/Caucasian/European Heritage555754166
Multiple1012
08

Study locations

1 site
  • Salus Research
    Fort Wayne, Indiana 46825, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trialregister@haleon.com.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Mar 2025, 3 months.

Results were first posted in Mar 2026, 1 year after primary completion.

Of 45 industry-sponsored interventional studies with no phase under Dental Plaque, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 3 months is above that.

Counting every sponsor, half of 178 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2024
First posted
Oct 26, 2024
StartActual
Nov 18, 2024
Primary completionActual
Mar 11, 2025
CompletionActual
Mar 11, 2025
Results first posted
Mar 18, 2026
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06660069
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Oct 26, 2024
Start date
Nov 18, 2024
Primary completion
Mar 11, 2025
Completion
Mar 11, 2025
Results posted
Mar 18, 2026
Last update
Mar 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion